Laura Hamill - 07 Aug 2025 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Reporting relationship: Director
Issuer ticker: JAZZ
Reported as of: 07 Aug 2025
Net transaction value: -$200,807
SEC form: 4
Accepted by SEC: 11 Aug 2025, 17:44:31 UTC
Prior SEC filing: 02 Jul 2025
Next SEC filing: 19 Sep 2025
Source filing: View source filing
Reporting owner signature: By: /s/Adam Guttmann, as attorney in fact For: Laura Hamill

Key filing fact

Laura Hamill filed Form 4 for Jazz Pharmaceuticals plc (JAZZ) on 11 Aug 2025.

Key facts

This page summarizes Laura Hamill's Form 4 filing for Jazz Pharmaceuticals plc (JAZZ).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 11 Aug 2025, 17:44.

Change

Previous filing in this sequence was filed on 02 Jul 2025.
Current net transaction value: -$200,807.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001751804 Primary reporting owner

Hamill Laura

Relationship: Director
Address: 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, IRELAND
Signature: By: /s/Adam Guttmann, as attorney in fact For: Laura Hamill
Signature date: 11 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

JAZZ transaction

Ordinary Shares

Award

Transaction value: $0
Shares: +3,507
Change %: +67%
Price: $0.000000
Shares after: 8,738
Date: 07 Aug 2025
Ownership: Direct
Footnotes: F1

JAZZ transaction

Ordinary Shares

Tax liability

Transaction value: $200,807
Shares: -1,805
Change %: -21%
Price: $111.25
Shares after: 6,933
Date: 08 Aug 2025
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 24, 2026.

Footnote F2

Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.